Clinical trials: mFOLFOX6
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00321828
- Testing
- bevacizumab, fluorouracil, leucovorin
- Where
- 163 sites in United States
- Volunteers
- 90 people
- Sponsor
- NSABP Foundation Inc
Metastatic Colorectal Cancer
First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
The association of FOLFOX (5-fluoruracil, folinic acid, and oxaliplatin) and pan is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients.
- Trial name
- TRIPLETE (NCT03231722)
- Testing
- Panitumumab, Irinotecan, Oxaliplatin
- Where
- 4 sites in Italy
- Volunteers
- 435 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Adenocarcinoma, Stomach Cancer
A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
This research study is being down to find what, effects, good and/or bad, adding Pembrolizumab to standard chemotherapy mFOLFOX before and after surgery have on the patient and the patient's cancer.
- Trial name
- NCT02943603
- Testing
- mFLOFOX6 + pembrolizumab
- Where
- United States
- Sponsor
- Weijing Sun, MD, FACP
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol…
- Trial name
- ATOM (NCT01836653)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- EPS Corporation
Rectal Cancer, Liver Metastasis
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
Radical treatment of primary rectal cancer with synchronous distant metastases includes surgical resection of primary and metastatic lesion.
- Conditions
- Rectal Cancer, Liver Metastasis, Lung Metastasis
- Trial name
- NCT01923987
- Testing
- Short Course Radiotherapy, Chemotherapy, Delayed Surgery
- Where
- 2 sites in South Korea
- Volunteers
- 39 people
- Sponsor
- Korea Cancer Center Hospital
Colorectal Cancer
Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic…
- Trial name
- NCT01378143
- Testing
- OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI
- Where
- 7 sites in Canada
- Volunteers
- 53 people
- Sponsor
- Oncozyme Pharma Inc.
Rectal Cancer
FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study
Preoperative 5FU based chemoradiotherapy is still the standard of treatment for locally advanced rectal cancer. About 15-20% of patients would achieve pathologic complete response (pCR) after neoadjuvant CRT, and the survival…
- Trial name
- FOTAC (NCT02887313)
- Testing
- mFOLFOX6, Radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
In this study, Erlotinib and 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (a regimen known also as FOLFOX-6) will be the chemotherapy study drugs.
- Conditions
- Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
- Trial name
- NCT00591123
- Testing
- FOLFOX, 5-FU, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Translational Oncology Research International
Rectal Cancer
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative…
- Trial name
- PIER (NCT03000374)
- Testing
- Panitumumab, 5Fluorouracil, Oxaliplatin
- Where
- 11 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Neoplasms
Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
This multi-center, open-label, non-randomized, non-placebo-controlled, Phase I study will define the safety profile and tumor response profile of the multi-kinase inhibitor BAY73-4506 as oral treatment in combination with the…
- Trial name
- NCT00934882
- Testing
- Regorafenib (BAY73-4506)
- Where
- 7 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Bayer
Colorectal Cancer
Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type…
- Trial name
- PARADIGM (NCT02394795)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Where
- 155 sites in Japan
- Volunteers
- 823 people
- Sponsor
- Takeda
Metastatic Pancreatic Cancer
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
People are being asked to participate in this study who have metastatic pancreatic cancer (cancer that has spread to other parts of the body).
- Trial name
- NCT01489865
- Testing
- ABT-888, mFOLFOX-6
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Georgetown University
Colorectal Cancer
Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer
Studies suggest that the addition of antiangiogenic agents to conventional therapeutic strategies, e.g., chemotherapy, radiation, or other tumor-targeting agents, will increase clinical efficacy.
- Trial name
- NCT01529164
- Testing
- Endostatins (Endostar), Oxaliplatin, Leucovorin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Chinese Academy of Medical Sciences
Colo-rectal Cancer, Capecitabine
First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes
This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS and BRAF…
- Conditions
- Colo-rectal Cancer, Capecitabine, Cetuximab
- Trial name
- CAPCET (NCT05022030)
- Testing
- mCapOX plus cetuximab, mFOLFOX6 plus cetuximab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- West China Hospital
Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Neoadjuvant immunotherapy has shown promising therapeutic effects in mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
- Trial name
- BASKETⅢ (NCT06791512)
- Testing
- mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Jun Huang
Metastatic Colorectal Cancer
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
This was a phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03176264
- Testing
- PDR001, bevacizumab, mFOLFOX6
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasm
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
This trial will evaluate the combination treatment of established chemotherapy regimen mFOLFOX6 with Selinexor, an oral Selective Inhibitor Of Nuclear Export, in patients with metastatic Colorectal Cancer.
- Trial name
- SENTINEL (NCT02384850)
- Testing
- Selinexor, Oxaliplatin, 5-FU
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 10 people
- Sponsor
- GSO Global Clinical Research BV
Esophagogastric Adenocarcinoma, Metastatic Disease
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)
This is a prospective, multicenter, randomized, placebo-controlled, triple-blind phase II trial. The randomization will be a 1:1 randomization (experimental arm:control arm).
- Conditions
- Esophagogastric Adenocarcinoma, Metastatic Disease, No Previous Chemotherapy for Metastatic Esophagogastric Cancer
- Trial name
- MEGAN (NCT02856867)
- Testing
- Nintedanib, Fluorouracil, Leucovorin
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Rectal Cancer, Cancer of the Rectum
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
This phase II trial will investigate the combination of adjuvant 5-fluorouracil, radiation, and bevacizumab in patients with stage II and III rectal cancer, followed by FOLFOX6 and bevacizumab.
- Conditions
- Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
- Trial name
- NCT00308516
- Testing
- 5-Fluorouracil, Bevacizumab, Radiation Therapy
- Where
- 14 sites in United States
- Volunteers
- 66 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer
Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer
This is a randomized, multicenter study designed to evaluate the progression free survival of the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV and Oxaliplatin) as first-line treatment…
- Trial name
- NCT00721916
- Testing
- SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
- Where
- Japan
- Volunteers
- 107 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.